No.	Year	Category	Country	Citation	Journal	Type	PMID	Article
1	2008	drug therapy	U.S	276	J Invest Dermatol	Research Support	18200064	Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008 May;128(5):1207-11. doi: 10.1038/sj.jid.5701213. Epub 2008 Jan 17.
2	2004	drug therapy	U.S	231	J Exp Med	Comparative Study	14707118	Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004 Jan 5;199(1):125-30. doi: 10.1084/jem.20030451.
3	1999	immunoconjugates	U.S	132	J Clin Invest	Clinical Trial	10225967	Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999 May;103(9):1243-52. doi: 10.1172/JCI5857.
4	1999	drug therapy	U.S	92	J Invest Dermatol	Comparative Study	10571730	Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 J Invest Dermatol. 1999 Nov;113(5):752-9. doi: 10.1046/j.1523-1747.1999.00749.x.
5	2009	drug therapy	U.S	90	J Allergy Clin Immunol	Clinical Trial	19895991	Zaba LC, Su獺rez-Fari簽as M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009 Nov;124(5):1022-10.e1-395. doi: 10.1016/j.jaci.2009.08.046.
6	2009	drug therapy	Germany	84	J Eur Acad Dermatol Venereol	Practice Guideline	19712190	Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, H繹nigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009 Oct;23 Suppl 2:1-70. doi: 10.1111/j.1468-3083.2009.03389.x.
7	2002	immunoconjugates	U.S	77	J Am Acad Dermatol	Research Support	11756941	Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002 Jan;46(1):1-23; quiz 23-6. doi: 10.1067/mjd.2002.120568.
8	1994	drug therapy	Germany	74	J Invest Dermatol	Research Support	8106745	Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum B羹schenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994 Feb;102(2):145-9. doi: 10.1111/1523-1747.ep12371752.
9	2005	drug therapy	U.S	72	Ann Rheum Dis	Review	15708932	Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii30-6. doi: 10.1136/ard.2004.031120.
10	2005	drug therapy	U.S	72	Proc Natl Acad Sci U S A	Clinical Trial	15671179	Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2075-80. doi: 10.1073/pnas.0409569102. Epub 2005 Jan 25.
11	2004	drug therapy	South Korea	70	Trends Immunol	Research Support	15145319	Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol. 2004 Jun;25(6):295-305. doi: 10.1016/j.it.2004.03.006.
12	2004	drug therapy	U.S	65	J Invest Dermatol	Clinical Trial	15610511	Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE, Mascelli MA. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004 Dec;123(6):1037-44. doi: 10.1111/j.0022-202X.2004.23448.x.
13	1996	drug therapy	Netherlands	57	Eur J Immunol	Research Support	8814248	de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996 Sep;26(9):2067-74. doi: 10.1002/eji.1830260916.
14	2015	drug therapy	Germany	55	J Eur Acad Dermatol Venereol	Practice Guideline	26481193	Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kem矇ny L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94. doi: 10.1111/jdv.13354. Epub 2015 Oct 19.
15	2015	drug therapy	U.S	51	Dermatol Clin	Research Support	25412780	Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015 Jan;33(1):13-23. doi: 10.1016/j.det.2014.09.002.
16	2007	drug therapy	Canada	50	Arch Dermatol	Case Reports	17310002	de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007 Feb;143(2):223-31. doi: 10.1001/archderm.143.2.223.
17	2002	genetics	Japan	46	J Dermatol Sci	Journal Article	12413772	Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H, Asano N, Kishimoto M, Tanida Y, Kakinuma T, Mitsui H, Tada Y, Wakugawa M, Torii H, Komine M, Asahina A, Tamaki K. Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002 Nov;30(2):161-6. doi: 10.1016/s0923-1811(02)00072-5.
18	2001	drug therapy	Italy	44	J Allergy Clin Immunol	Comparative Study	11344355	Giustizieri ML, Mascia F, Frezzolini A, De Pit? O, Chinni LM, Giannetti A, Girolomoni G, Pastore S. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol. 2001 May;107(5):871-7. doi: 10.1067/mai.2001.114707.
19	2000	drug therapy	U.S	44	J Exp Med	Journal Article	10974034	Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial J Exp Med. 2000 Sep 4;192(5):681-94. doi: 10.1084/jem.192.5.681.
20	2004	drug therapy	Portugal	41	Br J Dermatol	Research Support	15149504	Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004 May;150(5):917-28. doi: 10.1111/j.1365-2133.2004.05984.x.
21	2014	drug therapy	U.S	39	PLoS One	Journal Article	24587313	Chiricozzi A, Nograles KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM, Gulati N, Mitsui H, Guttman-Yassky E, Su獺rez-Fari簽as M, Krueger JG. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One. 2014 Feb 28;9(2):e90284. doi: 10.1371/journal.pone.0090284. eCollection 2014
22	2010	drug therapy	Japan	39	J Dermatol	Clinical Trial	20507398	Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010 Apr;37(4):299-310. doi: 10.1111/j.1346-8138.2009.00748.x.
23	2010	drug therapy	U.S	39	Semin Cutan Med Surg	Research Support	20430301	Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg. 2010 Mar;29(1):3-9. doi: 10.1016/j.sder.2010.03.001.
24	2013	dermatitis	U.S	38	PLoS One	Research Support	24386404	Su獺rez-Fari簽as M, Arbeit R, Jiang W, Ortenzio FS, Sullivan T, Krueger JG. Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS One. 2013 Dec 27;8(12):e84634. doi: 10.1371/journal.pone.0084634. eCollection 2013
25	2010	drug therapy	U.S	37	J Allergy Clin Immunol	Research Support	20471070	Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Johnson-Huang LM, Nograles KE, White TR, Pierson KC, Lentini T, Su獺rez-Fari簽as M, Lowes MA, Krueger JG. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol. 2010 Jun;125(6):1261-1268.e9. doi: 10.1016/j.jaci.2010.03.018. Epub 2010 May 14.
26	2015	drug therapy	Denmark	35	Br J Dermatol	Comparative Study	25132294	Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015 Jan;172(1):244-52. doi: 10.1111/bjd.13343. Epub 2014 Nov 30.
27	2009	genetics	Germany	33	J Invest Dermatol	Research Support	18800148	H羹ffmeier U, Lascorz J, B繹hm B, Lohmann J, Wendler J, M繹ssner R, Reich K, Traupe H, Kurrat W, Burkhardt H, Reis A. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol. 2009 Feb;129(2):355-8. doi: 10.1038/jid.2008.233. Epub 2008 Sep 18
28	2011	drug therapy	Denmark	32	Br J Dermatol	Research Support	21219290	Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011 May;164(5):1091-6. doi: 10.1111/j.1365-2133.2011.10213.x. Epub 2011 Apr 11.
29	2008	drug therapy	Poland	32	Clin Chim Acta	Review	18445484	Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, Nockowski P, Osemlak P, Paszkowski T, Roli?ski JM. Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008 Aug;394(1-2):7-21. doi: 10.1016/j.cca.2008.04.005. Epub 2008 Apr 12.
30	2004	drug therapy	Netherlands	32	Eur J Immunol	Research Support	14768062	Litjens NH, Rademaker M, Ravensbergen B, Rea D, van der Plas MJ, Thio B, Walding A, van Dissel JT, Nibbering PH. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol. 2004 Feb;34(2):565-75. doi: 10.1002/eji.200324174.
31	2014	drug therapy	China	31	Clin Immunol	Research Support	24316592	Zhao M, Wang LT, Liang GP, Zhang P, Deng XJ, Tang Q, Zhai HY, Chang CC, Su YW, Lu QJ. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol. 2014 Jan;150(1):22-30. doi: 10.1016/j.clim.2013.10.009. Epub 2013 Oct 25
32	2001	drug therapy	U.S	28	Lab Invest	Journal Article	11310827	Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest. 2001 Mar;81(3):335-47. doi: 10.1038/labinvest.3780242.
33	2012	immunoconjugates	U.S	27	Dis Model Mech	Research Support	22730473	Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech. 2012 Jul;5(4):423-33. doi: 10.1242/dmm.009092.
34	2000	immunoconjugates	U.S	27	J Autoimmun	Comparative Study	10648117	Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun. 2000 Feb;14(1):63-78. doi: 10.1006/jaut.1999.0343.
35	2009	drug therapy	China	26	J Immunol	Research Support	19752240	Wang H, Syrovets T, Kess D, B羹chele B, Hainzl H, Lunov O, Weiss JM, Scharffetter-Kochanek K, Simmet T. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J Immunol. 2009 Oct 1;183(7):4755-63. doi: 10.4049/jimmunol.0900521. Epub 2009 Sep 14
36	2000	drug therapy	U.S	26	J Am Acad Dermatol	Multicenter Study	10688712	Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000 Mar;42(3):428-35. doi: 10.1016/s0190-9622(00)90214-7.
37	2018	drug therapy	U.S	25	J Immunol	Research Support	30181299	Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018 Sep 15;201(6):1605-1613. doi: 10.4049/jimmunol.1800013.
38	2007	drug therapy	U.S	25	J Transl Med	Clinical Trial	17555598	Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med. 2007 Jun 7;5:27. doi: 10.1186/1479-5876-5-27.
39	2011	drug therapy	Italy	24	Dermatol Ther	Clinical Trial	21910803	Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, Esposito M, Tiberti S, Chimenti S, DE Lorenzo A. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-帢 treatment. Dermatol Ther. 2011 Jul-Aug;24(4):446-51. doi: 10.1111/j.1529-8019.2011.01439.x.
40	2002	genetics	Germany	24	J Invest Dermatol	Research Support	11851889	Reich K, M繹ssner R, K繹nig IR, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol. 2002 Jan;118(1):155-63. doi: 10.1046/j.0022-202x.2001.01642.x.
41	2011	drug therapy	Germany	23	J Dtsch Dermatol Ges	Review	21251229	Sabat R, Wolk K. Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis. J Dtsch Dermatol Ges. 2011 Jul;9(7):518-23. doi: 10.1111/j.1610-0387.2011.07611.x. Epub 2011 Jan 21.
42	2003	drug therapy	Japan	22	J Allergy Clin Immunol	Research Support	12642842	Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H, Tada Y, Wakugawa M, Watanabe T, Torii H, Komine M, Asahina A, Nakamura K, Tamaki K. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol. 2003 Mar;111(3):592-7. doi: 10.1067/mai.2003.114.
43	2003	drug therapy	U.S	22	J Am Acad Dermatol	Clinical Trial	12522373	Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade AA, Wagner CL. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003 Jan;48(1):68-75. doi: 10.1067/mjd.2003.10.
44	2000	drug therapy	U.S	22	J Am Acad Dermatol	Clinical Trial	11004613	Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, Solodkina G, Grossman R, Gisoldi E, Phillips S, Neisler HM, Krueger JG. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol. 2000 Oct;43(4):595-604. doi: 10.1067/mjd.2000.107945.
45	1994	drug therapy	Germany	22	Eur J Immunol	Research Support	8125129	Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, Plewig G. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol. 1994 Mar;24(3):593-8. doi: 10.1002/eji.1830240315.
46	2007	genetics	Taiwan	21	Br J Dermatol	Research Support	17388919	Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, Huang CH, Lee DD, Liu HN, Wang WJ, Tsai SF. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol. 2007 May;156(5):899-905. doi: 10.1111/j.1365-2133.2007.07820.x. Epub 2007 Mar 28.
47	2017	drug therapy	U.S	20	Annu Rev Med	Research Support	27686018	Kim J, Krueger JG. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annu Rev Med. 2017 Jan 14;68:255-269. doi: 10.1146/annurev-med-042915-103905. Epub 2016 Sep 23.
48	2010	drug therapy	U.S	20	Br J Dermatol	Research Support	20716221	Anderson KS, Petersson S, Wong J, Shubbar E, Lokko NN, Carlstr繹m M, Enerb瓣ck C. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol. 2010 Nov;163(5):1085-9. doi: 10.1111/j.1365-2133.2010.09990.x.
49	2007	drug therapy	Germany	20	Brain Behav Immun	Research Support	16714097	Buske-Kirschbaum A, Kern S, Ebrecht M, Hellhammer DH. Altered distribution of leukocyte subsets and cytokine production in response to acute psychosocial stress in patients with psoriasis vulgaris. Brain Behav Immun. 2007 Jan;21(1):92-9. doi: 10.1016/j.bbi.2006.03.006. Epub 2006 May 22.
50	2016	drug therapy	Belgium	19	Br J Dermatol	Review	27117954	Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol. 2016 Nov;175(5):892-901. doi: 10.1111/bjd.14703. Epub 2016 Aug 23.
51	2004	drug therapy	Netherlands	19	Br J Dermatol	Journal Article	15149496	Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol. 2004 May;150(5):852-9. doi: 10.1111/j.1365-2133.2004.05863.x.
52	2017	drug therapy	Japan	18	Exp Dermatol	Research Support	28191680	Niyonsaba F, Kiatsurayanon C, Chieosilapatham P, Ogawa H. Friends or Foes? Host defense (antimicrobial) peptides and proteins in human skin diseases. Exp Dermatol. 2017 Nov;26(11):989-998. doi: 10.1111/exd.13314. Epub 2017 Apr 27.
53	2001	genetics	Germany	18	J Invest Dermatol	Research Support	11710947	Vollmer S, Menssen A, Prinz JC. Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol. 2001 Nov;117(5):1296-301. doi: 10.1046/j.0022-202x.2001.01494.x.
54	1998	drug therapy	Japan	18	Br J Dermatol	Journal Article	9536224	Fukuoka M, Ogino Y, Sato H, Ohta T, Komoriya K, Nishioka K, Katayama I. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Br J Dermatol. 1998 Jan;138(1):63-70. doi: 10.1046/j.1365-2133.1998.02027.x.
55	1995	drug therapy	Germany	18	J Immunol	Research Support	7561119	Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, G羹rtler L, Riethm羹ller G, Prinz JC. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol. 1995 Oct 15;155(8):4078-83.
56	1993	drug therapy	Germany	18	J Immunol	Research Support	7691948	Schulz BS, Michel G, Wagner S, S羹ss R, Beetz A, Peter RU, Kem矇ny L, Ruzicka T. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol. 1993 Oct 15;151(8):4399-406.
57	2017	drug therapy	Canada	17	J Invest Dermatol	Controlled Trial	28286061	Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, Maari C, Delorme I, Lynde CW, Tardif JC. TNF-帢 Antagonist and Vascular Inflammation in Patients with Psoriasis?Vulgaris: A Randomized Placebo-Controlled Study. J Invest Dermatol. 2017 Aug;137(8):1638-1645. doi: 10.1016/j.jid.2017.02.977. Epub 2017 Mar 9.
58	2005	drug therapy	Japan	17	J Allergy Clin Immunol	Research Support	16275389	Kanda N, Koike S, Watanabe S. IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol. 2005 Nov;116(5):1144-50. doi: 10.1016/j.jaci.2005.08.014. Epub 2005 Sep 26.
59	2016	drug therapy	U.S	16	Br J Dermatol	Comparative Study	26189551	Chiricozzi A, Su獺rez-Fari簽as M, Fuentes-Duculan J, Cueto I, Li K, Tian S, Brodmerkel C, Krueger JG. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016 Jan;174(1):136-45. doi: 10.1111/bjd.14034. Epub 2015 Nov 11.
60	2013	drug therapy	U.S	16	Clin Immunol	Research Support	23314273	Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol. 2013 Feb;146(2):131-9. doi: 10.1016/j.clim.2012.12.004. Epub 2012 Dec 20
61	2011	drug therapy	Greece	16	Clin Exp Dermatol	Journal Article	21790728	Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG, Katsambas A. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011 Dec;36(8):845-50. doi: 10.1111/j.1365-2230.2011.04131.x. Epub 2011 Jul 25.
62	2004	drug therapy	U.S	16	Curr Opin Rheumatol	Review	15201593	Chamian F, Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol. 2004 Jul;16(4):331-7. doi: 10.1097/01.bor.0000129715.35024.50.
63	2001	drug therapy	Germany	16	Clin Exp Dermatol	Review	11422184	Prinz JC. Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol. 2001 Jun;26(4):326-32. doi: 10.1046/j.1365-2230.2001.00831.x.
64	1991	drug therapy	Japan	16	Arch Dermatol	Journal Article	1903629	Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M. Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Arch Dermatol. 1991 Jun;127(6):827-30.
65	2010	drug therapy	Germany	15	Am J Clin Dermatol	Review	20000870	Terhorst D, Kalali BN, Ollert M, Ring J, Mempel M. The role of toll-like receptors in host defenses and their relevance to dermatologic diseases. Am J Clin Dermatol. 2010;11(1):1-10. doi: 10.2165/11311110-000000000-00000.
66	2007	drug therapy	U.S	15	J Immunol	Comparative Study	17513795	Haider AS, Lowes MA, Gardner H, Bandaru R, Darabi K, Chamian F, Kikuchi T, Gilleaudeau P, Whalen MS, Cardinale I, Novitskaya I, Krueger JG. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol. 2007 Jun 1;178(11):7442-9. doi: 10.4049/jimmunol.178.11.7442.
67	2004	drug therapy	Japan	15	Clin Exp Dermatol	Journal Article	15550147	Teraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol. 2004 Nov;29(6):658-63. doi: 10.1111/j.1365-2230.2004.01638.x.
68	2003	drug therapy	U.S	15	J Am Acad Dermatol	Research Support	12894134	Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S112-7. doi: 10.1016/s0190-9622(03)01143-5.
69	2014	drug therapy	Italy	14	J Immunol Res	Review	25126586	Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on pustular variants. J Immunol Res. 2014;2014:964069. doi: 10.1155/2014/964069. Epub 2014 Jul 13.
70	2017	drug therapy	U.S	13	J Immunol	Clinical Trial	28389592	Zanin-Zhorov A, Weiss JM, Trzeciak A, Chen W, Zhang J, Nyuydzefe MS, Arencibia C, Polimera S, Schueller O, Fuentes-Duculan J, Bonifacio KM, Kunjravia N, Cueto I, Soung J, Fleischmann RM, Kivitz A, Lebwohl M, Nunez M, Woodson J, Smith SL, West RF, Berger M, Krueger JG, Ryan JL, Waksal SD. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J Immunol. 2017 May 15;198(10):3809-3814. doi: 10.4049/jimmunol.1602142. Epub 2017 Apr 7.
71	2016	drug therapy	U.S	13	J Allergy Clin Immunol	Research Support	26725996	Harden JL, Lewis SM, Lish SR, Su獺rez-Fari簽as M, Gareau D, Lentini T, Johnson-Huang LM, Krueger JG, Lowes MA. The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. J Allergy Clin Immunol. 2016 Jun;137(6):1830-1840. doi: 10.1016/j.jaci.2015.09.055. Epub 2015 Dec 22.
72	2014	drug therapy	Italy	13	J Biol Regul Homeost Agents	Multicenter Study	24750799	Roberti ML, Ricottini L, Capponi A, Sclauzero E, Vicenti P, Fiorentini E, Savoia C, Scornavacca G, Brazioli D, Gaio L, Giannetti R, Ignazzi C, Meloni G, Chinni LM. Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. J Biol Regul Homeost Agents. 2014 Jan-Mar;28(1):133-9.
73	2013	drug therapy	Hungary	13	J Am Acad Dermatol	Journal Article	23891393	J籀kai H, Szakonyi J, Kont獺r O, Marschalk籀 M, Szalai K, K獺rp獺ti S, Holl籀 P. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol. 2013 Oct;69(4):523-9. doi: 10.1016/j.jaad.2013.06.019. Epub 2013 Jul 23.
74	2009	drug therapy	Japan	13	Eur J Immunol	Research Support	19350575	Kanda N, Shibata S, Tada Y, Nashiro K, Tamaki K, Watanabe S. Prolactin enhances basal and IL-17-induced CCL20 production by human keratinocytes. Eur J Immunol. 2009 Apr;39(4):996-1006. doi: 10.1002/eji.200838852.
75	2007	genetics	Poland	13	Br J Dermatol	Research Support	17553030	Nedoszytko B, Szczerkowska-Dobosz A, Zab?otna M, Gle? J, Reba?a K, Roszkiewicz J. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol. 2007 Jul;157(1):165-7. doi: 10.1111/j.1365-2133.2007.07993.x. Epub 2007 Jun 6.
76	2006	drug therapy	U.S	13	Ernst Schering Res Found Workshop	Review	16329644	Skurkovich B, Skurkovich S. Inhibition of IFN-gamma as a method of treatment of various autoimmune diseases, including skin diseases. Ernst Schering Res Found Workshop. 2006;(56):1-27. doi: 10.1007/3-540-37673-9_1.
77	2013	drug therapy	China	12	J Huazhong Univ Sci Technolog Med Sci	Research Support	23904383	He Q, Chen HX, Li W, Wu Y, Chen SJ, Yue Q, Xiao M, Li JW. IL-36 cytokine expression and its relationship with p38 MAPK and NF-庥B pathways in psoriasis vulgaris skin lesions. J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):594-599. doi: 10.1007/s11596-013-1164-1. Epub 2013 Aug 1.
78	2012	drug therapy	Canada	12	Lab Invest	Research Support	22525430	Martin G, Gu矇rard S, Fortin MM, Rusu D, Soucy J, Poubelle PE, Pouliot R. Pathological crosstalk in vitro between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. Lab Invest. 2012 Jul;92(7):1058-70. doi: 10.1038/labinvest.2012.69. Epub 2012 Apr 23
79	2010	drug therapy	China	12	Br J Dermatol	Research Support	20222932	Yan KX, Fang X, Han L, Zhang ZH, Kang KF, Zheng ZZ, Huang Q. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br J Dermatol. 2010 Jul;163(1):48-56. doi: 10.1111/j.1365-2133.2010.09742.x. Epub 2010 Mar 5.
80	2008	drug therapy	U.S	12	J Invest Dermatol	Research Support	17928893	Haider AS, Cohen J, Fei J, Zaba LC, Cardinale I, Toyoko K, Ott J, Krueger JG. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol. 2008 Mar;128(3):655-66. doi: 10.1038/sj.jid.5701064. Epub 2007 Oct 11.
81	2004	drug therapy	Poland	12	Acta Dermatovenerol Croat	Journal Article	15072741	Nockowski P, Szepietowski JC, Ziarkiewicz M, Baran E. Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris. Acta Dermatovenerol Croat. 2004;12(1):2-6.
82	2003	drug therapy	Denmark	12	Arch Dermatol	Clinical Trial	14623703	Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB, S繪lvsten H, Ibsen HH, Knudsen L, Jensen P, Petersen JH, Menn矇 T, Baadsgaard O. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol. 2003 Nov;139(11):1433-9. doi: 10.1001/archderm.139.11.1433.
83	2003	drug therapy	U.S	12	Curr Opin Mol Ther	Case Reports	12669471	Skurkovich B, Skurkovich S. Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Curr Opin Mol Ther. 2003 Feb;5(1):52-7.
84	2003	drug therapy	Netherlands	12	Br J Dermatol	Research Support	12653735	Litjens NH, Nibbering PH, Barrois AJ, Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol. 2003 Mar;148(3):444-51. doi: 10.1046/j.1365-2133.2003.05153.x.
85	2017	drug therapy	China	11	Clin Immunol	Research Support	27856305	Wu P, Ma G, Zhu X, Gu T, Zhang J, Sun Y, Xu H, Huo R, Wang B, Shen B, Chen X, Li N. Cyr61/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK/NF-庥B pathway. Clin Immunol. 2017 Jan;174:53-62. doi: 10.1016/j.clim.2016.11.003. Epub 2016 Nov 14.
86	2016	drug therapy	Denmark	11	J Dermatol Sci	Comparative Study	26794805	Lovato P, Norsgaard H, Tokura Y, R繪pke MA. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J Dermatol Sci. 2016 Mar;81(3):153-64. doi: 10.1016/j.jdermsci.2015.12.009. Epub 2015 Dec 23.
87	2014	drug therapy	Netherlands	11	Br J Dermatol	Journal Article	24673245	Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, de Rie MA, Hooft L, Spuls PI. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014 Oct;171(4):875-83. doi: 10.1111/bjd.13001. Epub 2014 Aug 21.
88	2013	drug therapy	Japan	11	J Dermatol	Research Support	23915382	Shimauchi T, Hirakawa S, Suzuki T, Yasuma A, Majima Y, Tatsuno K, Yagi H, Ito T, Tokura Y. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol. 2013 Oct;40(10):805-12. doi: 10.1111/1346-8138.12248. Epub 2013 Aug 6.
89	2010	drug therapy	Japan	11	Hum Immunol	Research Support	20849904	Kanda N, Ishikawa T, Kamata M, Tada Y, Watanabe S. Increased serum leucine, leucine-37 levels in psoriasis: positive and negative feedback loops of leucine, leucine-37 and pro- or anti-inflammatory cytokines. Hum Immunol. 2010 Dec;71(12):1161-71. doi: 10.1016/j.humimm.2010.09.005. Epub 2010 Sep 16.
90	2010	drug therapy	Italy	11	Cytokine	Research Support	19879157	Deeva I, Mariani S, De Luca C, Pacifico V, Leoni L, Raskovic D, Kharaeva Z, Korkina L, Pastore S. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine. 2010 Feb;49(2):163-70. doi: 10.1016/j.cyto.2009.09.014. Epub 2009 Oct 29.
91	2005	drug therapy	U.S	11	BMC Dermatol	Case Reports	16109173	Lowes MA, Turton JA, Krueger JG, Barnetson RS. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol. 2005 Aug 18;5:9. doi: 10.1186/1471-5945-5-9.
92	2005	genetics	Estonia	11	J Invest Dermatol	Letter	15654990	M繹ssner R, Kingo K, Kleensang A, Kr羹ger U, K繹nig IR, Silm H, Westphal GA, Reich K. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005 Jan;124(1):282-4. doi: 10.1111/j.0022-202X.2004.23556.x.
93	2003	drug therapy	Japan	11	J Dermatol Sci	Research Support	14527734	Doi H, Shibata MA, Kiyokane K, Otsuki Y. Downregulation of TGFbeta isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris. J Dermatol Sci. 2003 Oct;33(1):7-16. doi: 10.1016/s0923-1811(03)00107-5.
94	2002	drug therapy	Austria	11	Rheumatol Int	Clinical Trial	12426660	Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int. 2002 Nov;22(6):227-32. doi: 10.1007/s00296-002-0246-3. Epub 2002 Sep 4
95	1992	drug therapy	U.S	11	J Invest Dermatol	Research Support	1545139	Nanney LB, Yates RA, King LE Jr. Modulation of epidermal growth factor receptors in psoriatic lesions during treatment with topical EGF. J Invest Dermatol. 1992 Mar;98(3):296-301. doi: 10.1111/1523-1747.ep12497963.
96	2012	drug therapy	Italy	10	J Clin Immunol	Journal Article	22699761	Antiga E, Volpi W, Cardilicchia E, Maggi L, Fil穫 L, Manuelli C, Parronchi P, Fabbri P, Caproni M. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. J Clin Immunol. 2012 Dec;32(6):1221-32. doi: 10.1007/s10875-012-9716-x. Epub 2012 Jun 15.
97	2012	drug therapy	India	10	Clin Chim Acta	Research Support	22609260	Elango T, Dayalan H, Subramanian S, Gnanaraj P, Malligarjunan H. Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients. Clin Chim Acta. 2012 Oct 9;413(19-20):1652-6. doi: 10.1016/j.cca.2012.05.007. Epub 2012 May 16.
98	2011	drug therapy	Denmark	10	J Eur Acad Dermatol Venereol	Journal Article	21108668	Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R. Responses to ustekinumab in the anti-TNF agent-na簿ve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1037-40. doi: 10.1111/j.1468-3083.2010.03914.x. Epub 2010 Nov 25.
99	2010	drug therapy	U.S	10	Clin Exp Rheumatol	Review	21044425	Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-帢. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S3-8. Epub 2010 Oct 28.